Xilio Therapeutics (XLO) Competitors

Xilio Therapeutics logo
$7.54 -0.16 (-2.08%)
Closing price 04:00 PM Eastern
Extended Trading
$7.62 +0.08 (+1.06%)
As of 05:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

XLO vs. IMRX, FATE, ELDN, PLX, and GALT

Should you buy Xilio Therapeutics stock or one of its competitors? Xilio Therapeutics's main competitors and comparable companies include Immuneering (IMRX), Fate Therapeutics (FATE), Eledon Pharmaceuticals (ELDN), Protalix BioTherapeutics (PLX), and Galectin Therapeutics (GALT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Xilio Therapeutics compare to Immuneering?

Xilio Therapeutics (NASDAQ:XLO) and Immuneering (NASDAQ:IMRX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Xilio Therapeutics has higher revenue and earnings than Immuneering. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xilio Therapeutics$43.77M1.22-$35.04M-$0.40N/A
ImmuneeringN/AN/A-$56.03M-$1.03N/A

In the previous week, Immuneering had 5 more articles in the media than Xilio Therapeutics. MarketBeat recorded 6 mentions for Immuneering and 1 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 0.69 beat Immuneering's score of 0.27 indicating that Xilio Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Xilio Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Immuneering
0 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Immuneering has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -20.89%. Immuneering's return on equity of -33.91% beat Xilio Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Xilio Therapeutics-20.89% -60.54% -24.76%
Immuneering N/A -33.91%-32.00%

Xilio Therapeutics presently has a consensus price target of $16.00, suggesting a potential upside of 112.20%. Immuneering has a consensus price target of $15.67, suggesting a potential upside of 352.79%. Given Immuneering's stronger consensus rating and higher probable upside, analysts plainly believe Immuneering is more favorable than Xilio Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xilio Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Immuneering
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.83

54.3% of Xilio Therapeutics shares are held by institutional investors. Comparatively, 67.7% of Immuneering shares are held by institutional investors. 7.5% of Xilio Therapeutics shares are held by insiders. Comparatively, 14.9% of Immuneering shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Xilio Therapeutics has a beta of -0.13, meaning that its stock price is 113% less volatile than the broader market. Comparatively, Immuneering has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market.

Summary

Immuneering beats Xilio Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Xilio Therapeutics compare to Fate Therapeutics?

Xilio Therapeutics (NASDAQ:XLO) and Fate Therapeutics (NASDAQ:FATE) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

54.3% of Xilio Therapeutics shares are owned by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are owned by institutional investors. 7.5% of Xilio Therapeutics shares are owned by insiders. Comparatively, 4.7% of Fate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Xilio Therapeutics has higher revenue and earnings than Fate Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xilio Therapeutics$43.77M1.22-$35.04M-$0.40N/A
Fate Therapeutics$6.65M18.65-$136.32M-$1.03N/A

In the previous week, Fate Therapeutics had 1 more articles in the media than Xilio Therapeutics. MarketBeat recorded 2 mentions for Fate Therapeutics and 1 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 0.69 beat Fate Therapeutics' score of 0.51 indicating that Xilio Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Xilio Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Fate Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Xilio Therapeutics has a net margin of -20.89% compared to Fate Therapeutics' net margin of -1,941.09%. Xilio Therapeutics' return on equity of -60.54% beat Fate Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Xilio Therapeutics-20.89% -60.54% -24.76%
Fate Therapeutics -1,941.09%-73.92%-45.16%

Xilio Therapeutics currently has a consensus price target of $16.00, suggesting a potential upside of 112.20%. Fate Therapeutics has a consensus price target of $5.80, suggesting a potential upside of 468.63%. Given Fate Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Fate Therapeutics is more favorable than Xilio Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xilio Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Fate Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

Xilio Therapeutics has a beta of -0.13, indicating that its share price is 113% less volatile than the broader market. Comparatively, Fate Therapeutics has a beta of 2.65, indicating that its share price is 165% more volatile than the broader market.

Summary

Xilio Therapeutics beats Fate Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Xilio Therapeutics compare to Eledon Pharmaceuticals?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

Eledon Pharmaceuticals has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.13, suggesting that its share price is 113% less volatile than the broader market.

Eledon Pharmaceuticals has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -20.89%. Xilio Therapeutics' return on equity of -60.54% beat Eledon Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Eledon PharmaceuticalsN/A -160.61% -55.54%
Xilio Therapeutics -20.89%-60.54%-24.76%

56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are owned by institutional investors. 9.6% of Eledon Pharmaceuticals shares are owned by insiders. Comparatively, 7.5% of Xilio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Xilio Therapeutics has higher revenue and earnings than Eledon Pharmaceuticals. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eledon PharmaceuticalsN/AN/A-$45.62M-$0.73N/A
Xilio Therapeutics$43.77M1.22-$35.04M-$0.40N/A

Eledon Pharmaceuticals currently has a consensus target price of $10.00, indicating a potential upside of 405.05%. Xilio Therapeutics has a consensus target price of $16.00, indicating a potential upside of 112.20%. Given Eledon Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Eledon Pharmaceuticals is more favorable than Xilio Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eledon Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Xilio Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Eledon Pharmaceuticals had 5 more articles in the media than Xilio Therapeutics. MarketBeat recorded 6 mentions for Eledon Pharmaceuticals and 1 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 0.69 beat Eledon Pharmaceuticals' score of 0.55 indicating that Xilio Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Eledon Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Xilio Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Eledon Pharmaceuticals beats Xilio Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Xilio Therapeutics compare to Protalix BioTherapeutics?

Protalix BioTherapeutics (NYSE:PLX) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

In the previous week, Protalix BioTherapeutics had 11 more articles in the media than Xilio Therapeutics. MarketBeat recorded 12 mentions for Protalix BioTherapeutics and 1 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 0.69 beat Protalix BioTherapeutics' score of -0.05 indicating that Xilio Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Protalix BioTherapeutics
0 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Xilio Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

16.5% of Protalix BioTherapeutics shares are owned by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are owned by institutional investors. 6.7% of Protalix BioTherapeutics shares are owned by insiders. Comparatively, 7.5% of Xilio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Protalix BioTherapeutics currently has a consensus price target of $12.00, indicating a potential upside of 316.67%. Xilio Therapeutics has a consensus price target of $16.00, indicating a potential upside of 112.20%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Protalix BioTherapeutics is more favorable than Xilio Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Protalix BioTherapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Xilio Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Xilio Therapeutics has a net margin of -20.89% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat Xilio Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Protalix BioTherapeutics-21.03% -30.89% -11.74%
Xilio Therapeutics -20.89%-60.54%-24.76%

Protalix BioTherapeutics has a beta of 0.01, meaning that its share price is 99% less volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.13, meaning that its share price is 113% less volatile than the broader market.

Protalix BioTherapeutics has higher revenue and earnings than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Protalix BioTherapeutics$84.69M2.87$8.31M$0.2511.52
Xilio Therapeutics$43.77M1.22-$35.04M-$0.40N/A

Summary

Protalix BioTherapeutics beats Xilio Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Xilio Therapeutics compare to Galectin Therapeutics?

Xilio Therapeutics (NASDAQ:XLO) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

Galectin Therapeutics has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -20.89%. Galectin Therapeutics' return on equity of 0.00% beat Xilio Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Xilio Therapeutics-20.89% -60.54% -24.76%
Galectin Therapeutics N/A N/A -138.82%

Xilio Therapeutics presently has a consensus price target of $16.00, suggesting a potential upside of 112.20%. Galectin Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 278.01%. Given Galectin Therapeutics' higher possible upside, analysts clearly believe Galectin Therapeutics is more favorable than Xilio Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xilio Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Galectin Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Galectin Therapeutics has lower revenue, but higher earnings than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xilio Therapeutics$43.77M1.22-$35.04M-$0.40N/A
Galectin TherapeuticsN/AN/A-$30.84M-$0.43N/A

54.3% of Xilio Therapeutics shares are owned by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are owned by institutional investors. 7.5% of Xilio Therapeutics shares are owned by insiders. Comparatively, 53.0% of Galectin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Xilio Therapeutics has a beta of -0.13, indicating that its share price is 113% less volatile than the broader market. Comparatively, Galectin Therapeutics has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market.

In the previous week, Galectin Therapeutics had 2 more articles in the media than Xilio Therapeutics. MarketBeat recorded 3 mentions for Galectin Therapeutics and 1 mentions for Xilio Therapeutics. Galectin Therapeutics' average media sentiment score of 1.20 beat Xilio Therapeutics' score of 0.69 indicating that Galectin Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Xilio Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Galectin Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Galectin Therapeutics beats Xilio Therapeutics on 8 of the 12 factors compared between the two stocks.

Get Xilio Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for XLO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

XLO vs. The Competition

MetricXilio TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$54.39M$4.06B$7.82B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E RatioN/A25.6832.7626.82
Price / Sales1.2216.068.565.70
Price / CashN/A22.9521.0121.90
Price / Book0.784.184.463.72
Net Income-$35.04M-$24.15M$3.52B$393.10M
7 Day Performance-11.61%-7.25%-5.47%-4.73%
1 Month Performance-11.81%-5.98%-4.57%-7.14%
1 Year Performance-25.65%-7.72%-1.79%-7.51%

Xilio Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
XLO
Xilio Therapeutics
2.5213 of 5 stars
$7.54
-2.1%
$16.00
+112.2%
-22.2%$54.39M$43.77MN/A76
IMRX
Immuneering
2.3136 of 5 stars
$3.85
+5.5%
$15.67
+306.9%
-44.6%$236.39MN/AN/A57
FATE
Fate Therapeutics
3.1323 of 5 stars
$1.77
-8.8%
$5.80
+227.7%
+18.3%$235.78M$4.75MN/A161
ELDN
Eledon Pharmaceuticals
1.8472 of 5 stars
$2.76
-3.8%
$10.00
+262.3%
+11.9%$233.22MN/AN/A33
PLX
Protalix BioTherapeutics
2.781 of 5 stars
$2.86
+11.3%
$12.00
+319.6%
+61.8%$230.44M$80.62MN/A226

Related Companies and Tools


This page (NASDAQ:XLO) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners